About Helicobacter Pylori Infection

Overview
Helicobacter pylori infection, also known as H. pylori infection, is a bacterial infection caused by a type of bacteria called Helicobacter pylori. This bacterium specifically grows in the human stomach and can cause different digestive problems (gastrointestinal disorders) including chronic gastritis (long lasting stomach inflammation), peptic ulcers (sores in the stomach or small intestine), and sometimes even stomach (gastric) cancer. H. pylori infection is considered a major risk factor for these conditions. It is estimated that more than half of the world's population is chronically infected with H. pylori, and the bacterium has co-evolved with humans for thousands of years. H. pylori causes illness in people because it has certain proteins that help them survive in the stomach and sticky parts (adherence factors) that help it attach to the stomach lining. These features allow it to interact with the body in harmful ways. Because it can lead to serious health problems, H. pylori has been classified as a Group 1 carcinogen by the International Agency for Research on Cancer (IARC).
Causes and Risk Factors

Helicobacter pylori (H. pylori) infection is caused by the bacterium Helicobacter pylori. This infection is mainly acquired during early childhood, especially in poor countries. It spreads when germs from an infected person’s feces or mouth get into someone else’s mouth (this is called fecal-oral or oral-oral transmission). This can happen through contaminated food or water, or by close contact with an infected person.

The non-modifiable risk factors for H. pylori infection cannot be changed or controlled. This includes:

  • Age: This infection is mainly acquired during early childhood.
  • Geography: People who live or were born in developing countries or regions with poor sanitation are at higher risk.
  • Family history: If close family members, such as parents or siblings, have an H. pylori infection, it increases the likelihood of exposure and infection due to close contact.

The modifiable risk factors for H. pylori infection can be influenced or changed. This includes:

  • Poor living conditions: Lower socio-economic status, poor hygiene, overcrowded homes, bed sharing, and the spread of germs through food or water are all factors that increase the risk of getting an H. pylori infection.
  • Nutrition: Balanced diets with high antioxidant properties may have protective effects against H. pylori infection. A study found that a higher dietary antioxidant index was associated with a lower risk of H. pylori infection among adults.

It's important to note that while these risk factors can increase the likelihood of acquiring H. pylori infection, not everyone exposed to the bacteria will develop an infection. Additionally, some individuals may be more likely to develop complications from the infection because of inherited traits or other factors.

Understanding the causes and risk factors of H. pylori infection can help in implementing preventive measures and promoting better hygiene practices to reduce the spread of this bacterial infection.

Symptoms

Many people with Helicobacter pylori (H. pylori) infection may not experience any symptoms for years. However, some individuals may develop various digestive (gastrointestinal) symptoms. The most common early symptoms of H. pylori infection include:

  • Nausea and vomiting
  • Bloating
  • Appetite changes
  • Frequent burping
  • Dull or burning stomach pain
  • Bad breath
  • Heartburn
  • Diarrhea
  • Unintentional weight loss

It's important to note that while H. pylori infection is a significant risk factor for the development of peptic ulcers and certain types of stomach cancer, not everyone will develop these conditions.

As the infection progresses or becomes more severe, other common symptoms may occur. These symptoms can vary depending on the individual and the stage of the infection. Some additional symptoms that may occur with later stages, progression, or higher severity of H. pylori infection include:

  • Abdominal pain
  • Functional dyspepsia (discomfort or pain in the upper abdomen)
  • Early fullness after eating
  • Belching

In some cases, older individuals with long-term H. pylori infection may have no or mild digestive symptoms. However, patients with treatment-resistant H. pylori infections or a history of treatment failure may experience more severe gastrointestinal symptoms.

Diagnosis

Diagnosing Helicobacter pylori (H. Pylori) Infection typically involves a combination of medical evaluations and laboratory tests. Here are the common examinations, tests, and procedures used to diagnose this infection:

  • Breath test: The urea breath test is a common way to check for H. pylori. . It involves drinking a solution with urea that has a special carbon atom. If H. pylori is present in the stomach, it will break down the urea, releasing carbon dioxide, which can be detected in the breath. A positive breath test means there is an active infection.
  • Stool antigen test: This test detects Helicobacter pylori antigens in a stool sample, which can indicate an active infection.
  • Blood tests: Blood tests can detect antibodies to Helicobacter pylori, indicating a previous or current infection. However, these tests may not differentiate between past and current infections.

In addition to these common diagnostic methods, there are additional examinations, tests, and procedures that can be used to determine the stage or severity of Helicobacter pylori infection:

  • Endoscopy: In cases where other tests are inconclusive or if complications are suspected, a medical professional may perform an endoscopy. During this procedure, a thin, flexible tube with a camera goes through the mouth to examine the stomach lining and collect tissue samples for biopsy. This provides direct visual evidence of infection and can also diagnose more serious conditions, such as cancer.
  • Histology: Histology is another type of test that can provide valuable information about how much inflammation is in the stomach lining and can also show if there are any precancerous lesions linked to Helicobacter pylori infection. It involves examining tissue samples collected during endoscopy under a microscope.
  • Cultures: Cultures from gastric biopsies are the best method for diagnosing Helicobacter pylori infection and are recommended for antibiotic susceptibility tests. This method helps detect antibiotic resistance in Helicobacter pylori.
  • Molecular methods: Molecular methods are mainly used to detect antibiotic resistance in Helicobacter pylori.

It's important to note that while invasive testing provides direct visual proof of infection and helps with diagnosing serious conditions, non-invasive tests like the breath tests, stool antigen tests, and blood tests are often used to diagnosing H. pylori infection.

These diagnostic methods help healthcare professionals determine whether an individual has an active H. pylori infection and assess its stage or severity if necessary.

Treatment Options

The goals of treatment for Helicobacter pylori (H. pylori) infection are to eliminate the bacteria and reduce symptoms, prevent complications such as peptic ulcers and gastric (stomach) cancer, and improve overall health.

  • The main medication types used to treat Helicobacter pylori nfection are antibiotics and proton pump inhibitors (PPIs). Antibiotics help to kill the bacteria, while PPIs reduce the production of stomach acid, which can help relieve symptoms and promote healing of the stomach lining.
  • Therapeutic procedures may also be recommended in some cases. One common procedure is endoscopy, which allows the doctor to visualize the stomach and take tissue samples for testing. This helps determine the severity of the infection and guides treatment decisions.
  • In addition to medications and procedures, lifestyle behavior changes can support the treatment of H. pylori infection. These changes may include avoiding foods that trigger symptoms, quitting smoking, reducing alcohol consumption, and managing stress levels. Making these lifestyle changes can help reduce inflammation in the stomach and promote healing.

It's important to note that treatment plans may vary based on factors such as antibiotic resistance in a specific region. Your healthcare provider will determine the most appropriate treatment plan for your individual needs. It's crucial to follow the prescribed treatment plan as directed by your healthcare provider to ensure successful elimination of the bacteria and reduce the risk of complications.

Successful treatment can eliminate the bacteria and reduce inflammation in the stomach lining. This can help relieve symptoms and prevent further complications such as peptic ulcers and gastric cancer. However, it's important to note that treatment may not be successful in all cases due to factors such as antibiotic resistance or non-compliance with medical recommendations.

Medication dosing may be affected by many factors. Check with your health care professional about dosing for your individual situation. Other side effects can occur. Check with your health care professional or read the information provided with your medication for additional side effect information.

Progression or Complications

Helicobacter pylori (H. pylori) infection can have different outcomes and complications depending on various factors. The natural progression of H. pylori infection over time can vary from person to person. In some cases, the infection may remain asymptomatic, meaning the person doesn't experience any noticeable symptoms or complications. However, in other cases, the infection can lead to various complications and health problems.

Complications commonly associated with Helicobacter pylori infection include:

  • Chronic gastritis: Helicobacter pylori infection is a major cause of chronic gastritis, which is inflammation of the stomach lining. This can lead to symptoms such as abdominal pain, bloating, nausea, and vomiting.
  • Peptic Ulcers: Helicobacter pylori infection is strongly associated with the development of peptic ulcers, which are open sores that form in the lining of the stomach or duodenum (the first part of the small intestine). Peptic ulcers can cause symptoms like abdominal pain, indigestion, and bleeding.
  • Gastric Cancer: Long-term infection with Helicobacter pylori increases the risk of developing gastric cancer. However, it's important to note that most people infected with Helicobacter pylori do not develop gastric cancer.
  • MALT Lymphoma: MALT lymphoma (mucosa-associated lymphoid tissue lymphoma) is a type of non-Hodgkin's lymphoma that can occur in the stomach as a result of chronic Helicobacter pylori infection.

If you suspect you have a Helicobacter pylori infection or are experiencing symptoms related to it, it's important to consult with your healthcare provider. They can perform appropriate tests and recommend the most suitable treatment options for your specific situation. Remember, always ask your doctor before trying any home remedies or over-the-counter medications for this condition.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393410
CurrentHelicobacter pyloriDiagnostics.
The high prevalence ofHelicobacter pyloriand the variety of gastroduodenal diseases caused by this pathogen necessitate the use of only accurate methods both for the primary diagnosis and for monitoring the eradication effectiveness. There is a broad spectrum of diagnostic methods available for detectingH. pylori. All methods can be classified as invasive or non-invasive. The need for upper endoscopy, different clinical circumstances, sensitivity and specificity, and accessibility defines the method chosen. This article reviews the advantages and disadvantages of the current options and novel developments in diagnostic tests forH. pyloridetection. The progress in endoscopic modalities has made it possible not only to diagnose precancerous lesions and early gastric cancer but also to predictH. pyloriinfection in real time. The contribution of novel endoscopic evaluation technologies in the diagnosis ofH. pylorisuch as visual endoscopy using blue laser imaging (BLI), linked color imaging (LCI), and magnifying endoscopy is discussed. Recent studies have demonstrated the capability of artificial intelligence to predictH. pyloristatus based on endoscopic images. Non-invasive diagnostic tests such as the urea breathing test and stool antigen test are recommended for primary diagnosis ofH. pyloriinfection. Serology can be used for initial screening and epidemiological studies. The histology showed its value in detectingH. pyloriand provided more information about the degree of gastric mucosa inflammation and precancerous lesions. Molecular methods are mainly used in detecting antibiotic resistance ofH. pylori. Cultures from gastric biopsies are the gold standard and recommended for antibiotic susceptibility tests.
PubMed Central
2021-08-12
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204246
Designing a novel ELISA method based onCagA, NapArecombinant antigens to increase sensitivity and specificity ofHelicobacter pyloriwhole cell antigen detection.
In this research, we designed a direct Enzyme Linked Immunoassay method to detectHelicobacter pyloriantigens in stool specimens.
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601641
Phenotypic and Genotypic Analysis of ResistantHelicobacter pyloriStrains Isolated from Children with Gastrointestinal Diseases.
Antibiotic resistance ofHelicobacter pyloriis currently a global issue. The aim of this study was to analyze actual antibiotic resistance rates ofH. pyloristrains isolated from children with primary infections and to compare the incidence of mutations that determine resistance to clarithromycin (CH) and metronidazole (MET) in children with different clinical diagnoses. A total of 91H. pyloristrains were isolated from 108 children with primary infections. Drug susceptibility testing of the strains was performed using E-test method. Classical sequencing of DNA fragments was used to detect point mutations for CH and MET resistance. Resistance to CH was detected in 31% of isolated strains (28/91), while resistance to MET and CH was detected in 35% (32/91) of strains. A2143G was the most frequently detected mutation and was dominant among strains isolated from children with peptic ulcer disease (80%). Mutations in therdxAgene were found significantly more frequently among MET-resistant strains than MET-sensitive strains (p= 0.03, Chi2= 4.3909). In children, a higher frequency ofH. pylorimultiresistant strains was observed compared with the previous study in the same area. Differences were found in the occurrence of point mutations amongH. pyloristrains resistant to CH isolated from children with different clinical diagnoses.
PubMed Central
2020-09-27
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450302
Association between dietary antioxidant index and risk of Helicobacter pylori infection among adults: a case-control study.
One of the most important risk factors for Helicobacter pylori (H. pylori) infection is nutrition. Balanced diets with high antioxidant properties may have protective effects against the consequences of this infection. In the current study, we aimed to investigate the association between the dietary antioxidant index and the risk of H. pylori infection among adults.
PubMed Central
2022-09-06
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514670
Helicobacter pyloriInfection in Geriatric Patients: Current Situation and Treatment Regimens.
Helicobacter pylori(H. pylori) has so far infected more than half the global population. It is the most important and controllable risk factor for gastric cancer. The elderly, who are at a higher incidence of the infection, are also commonly found to develop antibiotic resistance. The symptoms, diagnosis, clinical features (of gastric or extra-digestive diseases), and treatment ofH. pyloriinfection in the elderly, are different from that in the non-elderly. Health conditions, including comorbidities and combined medication have limited the use of regular therapies in elderly patients. However, they can still benefit from eradication therapy, thus preventing gastric mucosal lesions and gastric cancer. In addition, new approaches, such as dual therapy and complementary therapy, have the potential to treat older patients withH. pyloriinfection.
PubMed Central
2021-09-30
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308520
Impact of Dietary Patterns onH. pyloriInfection and the Modulation of Microbiota to Counteract Its Effect. A Narrative Review.
Helicobacter pylori (H. pylori)is a Gram-negative bacterium that colonizes the stomach and can induce gastric disease and intra-gastric lesions, including chronic gastritis, peptic ulcers, gastric adenocarcinoma, and mucosa-associated lymphoid tissue lymphoma. This bacterium is responsible for long-term complications of gastric disease. The conjunction of host genetics, immune response, bacterial virulence expression, diet, micronutrient availability, and microbiome structure influence the disease outcomes related to chronicH. pyloriinfection. In this regard, the consumption of unhealthy and unbalanced diets can induce microbial dysbiosis, which infection withH. pylorimay contribute to. However, to date, clinical trials have reported controversial results and current knowledge in this field is inconclusive. Here, we review preclinical studies concerning the changes produced in the microbiota that may be related toH. pyloriinfection, as well as the involvement of diet. We summarize and discuss the last approaches based on the modulation of the microbiota to improve the negative impact ofH. pyloriinfection and their potential translation from bench to bedside.
PubMed Central
2021-07-10
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137001
Helicobacter Pylori Infection and Lung Cancer: 
New Insights and Future Challenges.
Helicobacter pylori (H. pylori) is the causative agent of chronic gastritis and peptic ulcer diseases and is an important risk factor for the development functional dyspepsia, peptic ulceration, gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma. H. pylori has very high rates of infection in human populations, and it is estimated that over 50% of the world population is infected. Recently, certain extra-gastric manifestations, linked to H. pylori infection, have been widely investigated. Noteworthy, a growing body of evidences supports an association between H. pylori infection with lung cancer. The present review intend to highlight not only the most recent evidences supporting this association, but also some missed points, which must be considered to validate this emerging association.
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4129565
Comparison of half-dose and full-dose triple therapy regimens for Helicobacter pylori eradication in patients with end-stage renal disease.
The aim of this study was to compare the half-dose and full-dose triple therapy regimens for Helicobacter pylori (Hp) eradication in patients with end-stage renal disease.
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144303
Long-term follow-up ofHelicobacter pylorireinfection and its risk factors after initial eradication: a large-scale multicentre, prospective open cohort, observational study.
Helicobacter pylori(H. pylori) recurrence remains a significant public health concern. The study aimed to assessH. pylorireinfection rate and identify its risk factors in China. This prospective open cohort, observational study was performed at 18 hospitals across 15 provinces in China. Consecutive patients who received the successful initial eradication during 1 January 2012 and 31 December 2018 were eligible for enrolment.H. pylorirecurrence was defined as reinfection that occurred at more than the 12-month interval after successful initial eradication. Surveyed risk factors that might be associated with reinfection were preliminarily estimated by log-rank test and further determined by Cox regression model to calculate the hazard ratio (HR) and 95% confidence interval (CI). A total of 5193 subjects enrolled in the study. The follow-up intervals varied from 6 to 84 months with a general follow-up rate of 67.9%. Annual reinfection rate was 1.5% (95% CI: 1.2-1.8) per person-year.H. pylorireinfection was independently associated with the following five risk factors: minority groups (HR = 4.7, 95% CI: 1.6-13.9), the education at lower levels (HR = 1.7, 95% CI: 1.1-2.6), a family history of gastric cancer (HR = 9.9, 95% CI: 6.6-14.7), and the residence located in Western China (HR = 5.5, 95% CI: 2.6-11.5) following by in Central China (HR = 4.9, 95% CI: 3-8.1) (allP< 0.05). Reinfection rate ofH. pyloriin China is relatively low. Patients with specific properties of ethnic groups, education level, family history, or residence location appear to be at higher risk for reinfection.
PubMed Central
2020-03-11
/en/sources/healthline-is-h-pylori-contagious
Is H. pylori contagious?
Healthline
2023-10-11
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885385
Antibacterial activity of lactobacilli probiotics on clinical strains ofHelicobacter pylori.
Treatment ofHelicobacter pyloriinfection by common drugs may be associated with several problems such as antimicrobial resistance to commonly used antibiotics and side effects of employed drugs. Therefore, exploration of non-chemical compounds which are safer than chemical ones is becoming important as an alternative therapy. The purpose of this study was to evaluate the effects of lactic acid bacteria (LAB) against clinical strains ofH. pylori.
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297740
Notch Signaling Ligand Jagged1 Enhances Macrophage-Mediated Response toHelicobacter pylori.
Helicobacter pylori(H. pylori) is one of the gram-negative bacteria that mainly colonize the stomach mucosa and cause many gastrointestinal diseases, such as gastritis, peptic ulcer, and gastric cancer. Macrophages play a key role in eradicatingH. pylori. Recent data have shown that Notch signaling could modulate the activation and bactericidal activities of macrophages. However, the role of Notch signaling in macrophages againstH. pyloriremains unclear. In the present study, in the co-culture model of macrophages withH. pylori, the inhibition of Notch signaling using γ-secretase decreased the expression of inducible nitric oxide synthase (iNOS) and its product, nitric oxide (NO), and downregulated the secretion of pro-inflammatory cytokine and attenuated phagocytosis and bactericidal activities of macrophages toH. pylori. Furthermore, we identified that Jagged1, one of Notch signaling ligands, was both upregulated in mRNA and protein level in activated macrophages induced byH. pylori. Clinical specimens showed that the number of Jagged1+macrophages in the stomach mucosa fromH. pylori-infected patients was significantly higher than that in healthy control. The overexpression of Jagged1 promoted bactericidal activities of macrophages againstH. pyloriand siRNA-Jagged1 presented the opposite effect. Besides, the addition of exogenous rJagged1 facilitated the pro-inflammatory mediators of macrophages againstH. pylori, but the treatment of anti-Jagged1 neutralizing antibody attenuated it. Taken together, these results suggest that Jagged1 is a promoting molecule for macrophages againstH. pylori, which will provide insight for exploring Jagged1 as a novel therapeutic target for the control ofH. pyloriinfection.
PubMed Central
2021-07-08
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469559
A nationwide cohort study suggests clarithromycin-based therapy for Helicobacter pylori eradication is safe in patients with stable coronary heart disease and subsequent peptic ulcer disease.
Clarithromycin-based therapy is important for Helicobacter pylori eradication treatment. However, clarithromycin may increase cardiovascular risk. Hence, we investigated the association between clarithromycin use and outcomes in adults with stable coronary heart disease (CHD) and subsequent peptic ulcer disease (PUD).
PubMed Central
2022-09-12
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719659
Correlation Analysis ofHelicobacter pyloriInfection and Digestive Tract Symptoms in Children and Related Factors of Infection.
To analyze the correlation betweenHelicobacter pyloriinfection and digestive tract symptoms in children and other related factors, and to explore the risk factors ofH. pyloriinfection in children and the expression of inflammatory factors inH. pylori-positive andH. pylori-negative children.
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498082
Gastric Cancer Due to ChronicH. pyloriInfection: What We Know and Where We Are Going.
Helicobacter pyloriis an established cause of many gastrointestinal pathologies including peptic ulcer disease, gastritis, and gastric cancer. It is an entity that affects the global population, and its true nature has only been known since the 1980s. Although there is much known aboutH. pyloriincluding its pathophysiology, detection, and eradication, resistance to current therapy models is common. This is problematic because untreated or inadequately treatedH. pyloriincreases morbidity and mortality related to gastric cancer and peptic ulcer disease among others. In order to improve the treatment and reduce resistance, there is significant ongoing research identifying new detection and eradication methods forH. pylori. This review aims to highlight what has already been established regardingH. pylori's epidemiology, pathophysiology, detection, and treatment as well as the most current and novel research involving detection and treatment ofH. pylori.
PubMed Central
2022-08-25
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663549
Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial.
Previous studies have suggested that Helicobacter pylori (H. pylori) infection is associated with nonalcoholic fatty liver disease (NAFLD). The purpose of the present study was to investigate the effect of H. pylori eradication treatment on NAFLD patients. Two hundred NAFLD patients who tested positive for H. pylori infection were randomized into the H. pylori eradication treatment group or the control group. Metabolic and inflammatory parameters and FibroScan were measured in all subjects at baseline and 1 year after treatment. At 1 year after treatment, the decrease in metabolic indicators, such as fasting blood glucose, glycosylated haemoglobin, homeostasis model assessment of insulin resistance (HOMA-IR), triglycerides, body mass index and controlled attenuation parameter values, were more obvious in the treatment group. Moreover, the inflammatory indicators white blood count and high-sensitivity C-reactive protein (hs-CRP) and the inflammatory factors interleukin 6 (IL-6) and tumour necrosis factor-α (TNF-α) were also significantly decreased. H. pylori eradication can further reduce the metabolic indices of NAFLD and the degree of liver steatosis. H. pylori infection may participate in the occurrence and development of NAFLD through its influence on inflammatory factors. Thus, checking for the presence of H. pylori infection in patients at risk of NAFLD may be beneficial.
PubMed Central
2022-11-14
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995679
Comparison of multiple treatment regimens in children withHelicobacter pyloriinfection: A network meta-analysis.
Multiple regimens have been widely used in the eradication treatment ofHelicobacter pyloriinfection in children. However, there is a lack of comparison and evaluation of their effectiveness in different regions of the world.
PubMed Central
2023-02-23